Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

VANFLYTA 17.7 MG

QUIZARTINIB (QUIZARTINIB HYDROCHLORIDE) : 17.7 MG · DIN 02558351 · DAIICHI SANKYO PHARMA CANADA LIMITED

Health Canada status: MARKETED

What is VANFLYTA?

VANFLYTA 17.7 MG contains QUIZARTINIB (QUIZARTINIB HYDROCHLORIDE) : 17.7 MG. It is listed in the Health Canada Drug Product Database under DIN 02558351, held by DAIICHI SANKYO PHARMA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

Product details and regulatory record

DIN02558351
Brand nameVANFLYTA
Generic / active ingredientQUIZARTINIB (QUIZARTINIB HYDROCHLORIDE) : 17.7 MG
ManufacturerDAIICHI SANKYO PHARMA CANADA LIMITED
Strength17.7 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeL01EX11 QUIZARTINIB
BiosimilarNo
Health Canada statusMARKETED
Status date30-Oct-2025

What can be used instead?

Other Canadian products sharing ATC code L01EX11 QUIZARTINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
VANFLYTA26.5 MGTABLETDAIICHI SANKYO PHARMA CANADA LIMITEDMARKETEDDIN 02558378

Who else supplies QUIZARTINIB worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. QUIZARTINIB appears in 6 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for VANFLYTA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for VANFLYTA

Health Canada Drug Product Database (DPD), DIN 02558351. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.